COVID-19 drug development

From WikiMD.org
Jump to navigation Jump to search

COVID-19 Drug Development

COVID-19 drug development is the process of creating pharmacological agents for treating the disease caused by the SARS-CoV-2 virus, known as COVID-19.

Pronunciation

  • COVID-19: /ˈkoʊ.vɪd naɪnˈtiːn/
  • Drug Development: /drʌɡ dɪˈvɛləpmənt/

Etymology

The term "COVID-19" is an acronym derived from "coronavirus disease 2019". The term "drug development" refers to the process of bringing a new pharmaceutical drug to the market once a lead compound has been identified through the process of drug discovery.

Overview

COVID-19 drug development involves the use of various strategies, including the repurposing of existing drugs, the development of new drugs, and the testing of vaccine candidates. The process is guided by the principles of pharmacology, virology, and immunology.

Drug Repurposing

Drug repurposing, also known as drug repositioning, is a strategy for identifying new uses for approved or investigational drugs that are outside the scope of the original medical indication. In the context of COVID-19, this has involved the testing of drugs such as Remdesivir and Hydroxychloroquine.

New Drug Development

New drug development for COVID-19 involves the design and synthesis of new compounds that can inhibit the SARS-CoV-2 virus. This process involves biochemistry, molecular biology, and pharmacology.

Vaccine Development

Vaccine development for COVID-19 involves the creation of a biological preparation that provides active acquired immunity to the disease. This has involved the use of various technologies, including mRNA vaccines and vector vaccines.

Related Terms

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski